Pacific Edge (ASX:PEB) Shares Rise: Why Is the Stock Climbing?

Sonal Goyal

13 November 2026 01:19 PM AEDT

Pacific Edge (ASX:PEB) Shares Rise: Why Is the Stock Climbing?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Pacific Edge shares were trading at $0.23 during the 13 November 2026 session, up 6.98%.
The final Local Coverage Determination confirming Medicare coverage for Cxbladder Triage and Triage Plus was published on 6 November 2026.
The determination is scheduled to take effect on 20 December 2026.

During the Trading session on 13 November 2026, Pacific Edge (ASX:PEB) shares were trading at $0.23, up 6.98%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Pacific Edge is a cancer diagnostics company based in Dunedin, New Zealand, listed on the NZX and the ASX. Its latest update, dated 6 November 2026, confirmed Medicare coverage for its Cxbladder urine-based tests.

Final Medicare coverage determination

The final Local Coverage Determination for urine-based biomarkers in patients with microhaematuria has been published to the Medicare Coverage Database. It confirms Medicare coverage for Cxbladder Triage and Triage Plus, and establishes haematuria evaluation as a covered Medicare benefit. The determination takes effect in 45 days, on 20 December 2026.

Market opportunity and reimbursement

Pacific Edge said Cxbladder Triage and Triage Plus are now covered for patients with intermediate-risk microhaematuria, a group it estimates at about 1.14 million testing opportunities a year. The company said it is the only test covered under the final determination, while competing tests and generic billing codes are not covered. Medicare reimbursement is expected to increase the average selling price, supporting Revenue growth and operating leverage.

Sector context

Urine-based diagnostic tests for bladder cancer compete with cystoscopy and other tests, and coverage decisions can determine how quickly urologists adopt a test. Reimbursement is often the main Factor in the uptake of new diagnostics, which is why coverage decisions are closely watched across the sector.

Risks investors are watching

The coverage takes effect from 20 December 2026, so the financial benefit will not be felt until then. Adoption by urologists depends on clinical habits and the pace at which tests are ordered, and the company's estimate of testing opportunities is not a forecast of sales. Pricing pressure, competition and the company's cash position are also relevant.

What to watch ahead

Investors will look for the effective date of 20 December 2026, the company's next quarterly update on test volumes and average selling prices, and any changes to the Medicare position.

Final Word

Pacific Edge's latest update confirms Medicare coverage for two of its tests, with effect from late December. Early Volume and pricing data after the change takes effect will show how the coverage is reflected in its business.

FAQs

Q: Which Pacific Edge tests are covered by the final determination?

A: Cxbladder Triage and Triage Plus are confirmed as covered for intermediate-risk microhaematuria patients.

Q: When does the determination take effect?

A: It is scheduled to take effect on 20 December 2026.

Q: Where is Pacific Edge based?

A: The company is based in Dunedin, New Zealand, and is listed on the NZX and the ASX.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.